Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 14, Number 3—March 2008

Research

Mycobacterium ulcerans Disease, Peru

Humberto Guerra*, Juan Carlos Palomino†, Eduardo Falconí*‡, Francisco Bravo*, Ninoska Donaires*, Eric Van Marck§, and Françoise Portaels†Comments to Author 
Author affiliations: *Universidad Peruana Cayetano Heredia, Lima, Perú; †Institute of Tropical Medicine, Antwerp, Belgium; ‡Instituto Nacional de Salud del Perú, Lima, Perú; §University of Antwerp, Antwerp, Belgium;

Main Article

Table 1

Case descriptions of Buruli ulcer, Peru*

Patient no. Geographic
origin Age, y/sex Patient delay, mo Localized pain No. of lesions Sites Size of main lesion, cm Treatment
1 Marañón 18/M 8 Positive 2 Left knee 7 × 6 Lost to follow-up, no treatment
2 Huallaga 22/F 1 Positive 1 Left thigh 2 × 3 Lost to follow-up, no treatment
3 Iquitos 54/M 2 Positive 2 (right knee earlier, larger) Both knees 6 × 7 Antituberculous drugs and herbal medicines
4 Iquitos 58/F 8 Positive 5 (in a single group) Left gluteal region 12 × 16 (sum of all 5) Anti-Leishmania and herbal medicines
5 Tumbes 46/F 8 Positive 2
(1 lesion was a scar) Left foot 5 × 6 Lost to follow-up, no treatment
6 Iquitos 21/F 3 Positive 1 Right thigh 5 × 5 Antituberculous drugs (regimen 1) and surgery
7 Tumbes 34/F 2 Positive 4 Right thigh and leg 6 × 8 WHO BU antibiotics and surgery
8 Tumbes 45/M 1 Positive 2 Right middle finger 8 × 2 Antituberculous drugs (regimen 1) and surgery

*WHO, World Health Organization; BU, Buruli ulcer.

Main Article

TOP